Equity

BSF Health Sciences Absolute Return Fund

Overview

Important Information: Capital at Risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

All currency hedged share classes of this fund use derivatives to hedge currency risk. The use of derivatives for a share class could pose a potential risk of contagion (also known as spill-over) to other share classes in the fund. The fund’s management company will ensure appropriate procedures are in place to minimise contagion risk to other share class. Using the drop down box directly below the name of the fund, you can view a list of all share classes in the fund – currency hedged share classes are indicated by the word “Hedged” in the name of the share class. In addition, a full list of all currency hedged share classes is available on request from the fund’s management company

To the extent the Fund undertakes securities lending to reduce costs, the Fund will receive 62.5% of the associated revenue generated and the remaining 37.5% will be received by BlackRock as the securities lending agent. As securities lending revenue sharing does not increase the costs of running the Fund, this has been excluded from the ongoing charges.

Loading

Performance

Performance

Reinvestments

This product does not have any distributions data as of now.
This chart has been left intentionally blank as there is less than one year's performance data.
Returns not available as there is less than one year’s performance data.
Returns not available as there is less than one year’s performance data.
Returns not available as there is less than one year’s performance data.

The figures shown relate to past performance. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past

Share Class and Benchmark performance displayed in EUR, hedged share class benchmark performance is displayed in USD.

Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: Blackrock

Key Facts

Key Facts

Net Assets of Fund
as of 24/Jun/2024
USD 16,225,384
Fund Launch Date
03/Aug/2023
Fund Base Currency
USD
Target Benchmark 1
3 Month SOFR Compounded in Arrears plus 26.1 basis point spread
Initial Charge
0.00%
ISIN
LU2353382463
Performance Fee
20.00%
Minimum Subsequent Investment
EUR 10,000.00
Domicile
Luxembourg
Management Company
BlackRock (Luxembourg) S.A.
Dealing Settlement
Trade Date + 3 days
Bloomberg Ticker
BLSARIE
Share Class launch date
03/Aug/2023
Share Class Currency
EUR
Asset Class
Equity
SFDR Classification
Other
Ongoing Charges Figures
1.08%
Annual Management Fee
1.00%
Minimum Initial Investment
EUR 10,000,000.00
Use of Income
Accumulating
Regulatory Structure
UCITS
Morningstar Category
-
Dealing Frequency
Daily, forward pricing basis
SEDOL
BMYYH44

Portfolio Characteristics

Portfolio Characteristics

Number of Holdings
as of 31/May/2024
79
3y Beta
as of -
-
P/B Ratio
as of 31/May/2024
20.24
Standard Deviation (3y)
as of -
-
P/E Ratio
as of 31/May/2024
63.58

ESG Integration

ESG Integration

ESG integration is the practice of incorporating financially material environmental, social and governance (ESG) data or information into the investment decision process with the objective of enhancing risk-adjusted returns of our clients’ portfolios. Unless otherwise stated in Fund documentation or included within the Fund's investment objective, inclusion of this statement does not imply that the Fund has an ESG-aligned investment objective or strategy, but rather describes how ESG data or information is considered as part of the overall investment process.

The Fund manager includes ESG considerations in combination with other information in the research and decision phases of the investment process. The Fund manager conducts regular portfolio reviews between with the Risk and Quantitative Analysis group and with the Chief Investment Officers. Where appropriate, these reviews include discussion of the portfolio's exposure to material ESG risks, as well as exposure to sustainability-related business involvements, climate-related metrics, and other factors.

Risk Indicator

Risk Indicator

1
2
3
4
5
6
7
Low Risk High Risk
Typically low rewards Typically high rewards

Ratings

Holdings

Holdings

as of 31/May/2024
Name Weight (%)
ELEVANCE HEALTH INC 2.88
CENCORA INC 2.28
HCA HEALTHCARE INC 2.16
COOPER INC 2.10
DANAHER CORP 2.04
Name Weight (%)
BOSTON SCIENTIFIC CORP 1.97
THERMO FISHER SCIENTIFIC INC 1.93
LONZA GROUP AG 1.82
STRYKER CORP 1.76
BLUEPRINT MEDICINES CORP 1.52
Holdings subject to change

Exposure Breakdowns

Exposure Breakdowns

as of 31/May/2024

% of Market Value

Type Fund
as of 31/May/2024

% of Market Value

Type Fund
as of 31/May/2024

% of Market Value

Type Fund
as of 31/May/2024

% of Market Value

Type Fund
Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management. Allocations are subject to change.

Pricing & Exchange

Pricing & Exchange

Investor Class Currency NAV NAV Amount Change NAV % Change NAV As Of 52wk High 52wk Low ISIN
Class I2 Hedged EUR 105.37 0.15 0.14 25/Jun/2024 105.89 99.75 LU2353382463
Class I2 Hedged GBP 106.62 0.16 0.15 25/Jun/2024 106.92 99.77 LU2353382547
Class A2 USD 106.25 0.16 0.15 25/Jun/2024 106.57 99.76 LU2353382034
Class I2 Hedged CHF 103.24 0.14 0.14 25/Jun/2024 104.38 99.79 LU2353382620
Class D2 USD 106.66 0.16 0.15 25/Jun/2024 106.96 99.77 LU2353382208
Class I2 EUR 109.03 0.58 0.53 25/Jun/2024 109.55 98.92 LU2575169110
Class A2 EUR 108.40 0.57 0.53 25/Jun/2024 108.95 98.92 LU2575168906
Class Z2 USD 107.14 0.16 0.15 25/Jun/2024 107.42 99.77 LU2353382976
Class A2 Hedged EUR 104.77 0.15 0.14 25/Jun/2024 105.45 99.74 LU2353382117
Class D2 Hedged EUR 105.16 0.15 0.14 25/Jun/2024 105.73 99.75 LU2575169037
Class I2 USD 106.87 0.16 0.15 25/Jun/2024 107.16 99.77 LU2353382380

Portfolio Managers

Portfolio Managers

Erin Xie, PhD

 

Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios.

Xiang Liu, PhD

 

Xiang Liu, PhD, Managing Director and portfolio manager, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector.

Literature

Literature